PA
MRTX

Perceptive Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Perceptive Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200,000
Closed -$690K – 109
2023
Q2 		$690K Buy
+200,000
New +$8.24M 0.02% 86

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors's MRTX Position: Q3 2023 in Review

Perceptive Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 719,103 shares — an estimated $26M sold.

Perceptive Advisors first reported a position in MRTX in Q1 2016 and held it in 24 quarters. The position peaked at $811M in Q4 2020. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • Perceptive Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Perceptive Advisors sold 719,103 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $26M.
  • Perceptive Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2016 and held it in 24 quarters.
  • Perceptive Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $811M in Q4 2020.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.